

Tyler Jacks

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11823747/publications.pdf>

Version: 2024-02-01

240
papers

95,482
citations

867

120
h-index

1238

233
g-index

252
all docs

252
docs citations

252
times ranked

90145
citing authors

#	ARTICLE	IF	CITATIONS
1	<i>Smarca4</i> Inactivation Promotes Lineage-Specific Transformation and Early Metastatic Features in the Lung. <i>Cancer Discovery</i> , 2022, 12, 562-585.	7.7	48
2	A GATA4-regulated secretory program suppresses tumors through recruitment of cytotoxic CD8 T cells. <i>Nature Communications</i> , 2022, 13, 256.	5.8	8
3	Spatial genomics enables multi-modal study of clonal heterogeneity in tissues. <i>Nature</i> , 2022, 601, 85-91.	13.7	117
4	Lineage tracing reveals the phylodynamics, plasticity, and paths of tumor evolution. <i>Cell</i> , 2022, 185, 1905-1923.e25.	13.5	108
5	Deciphering the immunopeptidome in vivo reveals new tumour antigens. <i>Nature</i> , 2022, 607, 149-155.	13.7	38
6	Inducible de novo expression of neoantigens in tumor cells and mice. <i>Nature Biotechnology</i> , 2021, 39, 64-73.	9.4	32
7	Radiation-induced neoantigens broaden the immunotherapeutic window of cancers with low mutational loads. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	62
8	Protocol for single-cell ATAC sequencing using combinatorial indexing in mouse lung adenocarcinoma. <i>STAR Protocols</i> , 2021, 2, 100583.	0.5	9
9	Mitochondrial apoptotic priming is a key determinant of cell fate upon p53 restoration. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	20
10	<i>Rlf1</i> Mycl Gene Fusion Drives Tumorigenesis and Metastasis in a Mouse Model of Small Cell Lung Cancer. <i>Cancer Discovery</i> , 2021, 11, 3214-3229.	7.7	24
11	Live cell tagging tracking and isolation for spatial transcriptomics using photoactivatable cell dyes. <i>Nature Communications</i> , 2021, 12, 4995.	5.8	25
12	The CD155/TIGIT axis promotes and maintains immune evasion in neoantigen-expressing pancreatic cancer. <i>Cancer Cell</i> , 2021, 39, 1342-1360.e14.	7.7	119
13	Low neoantigen expression and poor T-cell priming underlie early immune escape in colorectal cancer. <i>Nature Cancer</i> , 2021, 2, 1071-1085.	5.7	57
14	Measuring kinetics and metastatic propensity of CTCs by blood exchange between mice. <i>Nature Communications</i> , 2021, 12, 5680.	5.8	18
15	Antigen dominance hierarchies shape TCF1+ progenitor CD8 T cell phenotypes in tumors. <i>Cell</i> , 2021, 184, 4996-5014.e26.	13.5	84
16	Conventional type I dendritic cells maintain a reservoir of proliferative tumor-antigen specific TCF-1+ CD8+ T cells in tumor-draining lymph nodes. <i>Immunity</i> , 2021, 54, 2338-2353.e6.	6.6	111
17	BRG1 Loss Predisposes Lung Cancers to Replicative Stress and ATR Dependency. <i>Cancer Research</i> , 2020, 80, 3841-3854.	0.4	32
18	Epigenomic State Transitions Characterize Tumor Progression in Mouse Lung Adenocarcinoma. <i>Cancer Cell</i> , 2020, 38, 212-228.e13.	7.7	140

#	ARTICLE	IF	CITATIONS
19	Emergence of a High-Plasticity Cell State during Lung Cancer Evolution. <i>Cancer Cell</i> , 2020, 38, 229-246.e13.	7.7	210
20	Keap1 mutation renders lung adenocarcinomas dependent on Slc33a1. <i>Nature Cancer</i> , 2020, 1, 589-602.	5.7	44
21	Urinary detection of lung cancer in mice via noninvasive pulmonary protease profiling. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	58
22	Endocrine-Exocrine Signaling Drives Obesity-Associated Pancreatic Ductal Adenocarcinoma. <i>Cell</i> , 2020, 181, 832-847.e18.	13.5	77
23	CRISPR-mediated modeling and functional validation of candidate tumor suppressor genes in small cell lung cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 513-521.	3.3	54
24	Dissecting cell-type-specific metabolism in pancreatic ductal adenocarcinoma. <i>ELife</i> , 2020, 9, .	2.8	61
25	A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies. <i>Science</i> , 2019, 365, 599-604.	6.0	265
26	Notum produced by Paneth cells attenuates regeneration of aged intestinal epithelium. <i>Nature</i> , 2019, 571, 398-402.	13.7	166
27	Identification of DHODH as a therapeutic target in small cell lung cancer. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	89
28	Enhanced adaptive immune responses in lung adenocarcinoma through natural killer cell stimulation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 17460-17469.	3.3	50
29	Commensal Microbiota Promote Lung Cancer Development via $\gamma\delta$ T Cells. <i>Cell</i> , 2019, 176, 998-1013.e16.	13.5	592
30	IL-33 Signaling Alters Regulatory T Cell Diversity in Support of Tumor Development. <i>Cell Reports</i> , 2019, 29, 2998-3008.e8.	2.9	53
31	MHC-II neoantigens shape tumour immunity and response to immunotherapy. <i>Nature</i> , 2019, 574, 696-701.	13.7	563
32	Adaptive and Reversible Resistance to Kras Inhibition in Pancreatic Cancer Cells. <i>Cancer Research</i> , 2018, 78, 985-1002.	0.4	35
33	Colonoscopy-based colorectal cancer modeling in mice with CRISPR-Cas9 genome editing and organoid transplantation. <i>Nature Protocols</i> , 2018, 13, 217-234.	5.5	74
34	Differences in Nanoparticle Uptake in Transplanted and Autochthonous Models of Pancreatic Cancer. <i>Nano Letters</i> , 2018, 18, 2195-2208.	4.5	20
35	Isoform-specific deletion of PKM2 constrains tumor initiation in a mouse model of soft tissue sarcoma. <i>Cancer & Metabolism</i> , 2018, 6, 6.	2.4	24
36	A Wnt-producing niche drives proliferative potential and progression in lung adenocarcinoma. <i>Nature</i> , 2017, 545, 355-359.	13.7	265

#	ARTICLE	IF	CITATIONS
37	In vivo genome editing and organoid transplantation models of colorectal cancer and metastasis. <i>Nature Biotechnology</i> , 2017, 35, 569-576.	9.4	248
38	Dicer loss and recovery induce an oncogenic switch driven by transcriptional activation of the oncofetal Imp1 family. <i>Genes and Development</i> , 2017, 31, 674-687.	2.7	16
39	Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis. <i>Nature Medicine</i> , 2017, 23, 1362-1368.	15.2	462
40	Survival of pancreatic cancer cells lacking KRAS function. <i>Nature Communications</i> , 2017, 8, 1090.	5.8	131
41	Quantitative proteomics identify Tenascin-C as a promoter of lung cancer progression and contributor to a signature prognostic of patient survival. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E5625-E5634.	3.3	116
42	Basic Mouse Methods for Clinician Researchers. , 2017, , 291-312.		2
43	Lung Adenocarcinoma Distally Rewires Hepatic Circadian Homeostasis. <i>Cell</i> , 2016, 165, 896-909.	13.5	195
44	Germline loss of PKM2 promotes metabolic distress and hepatocellular carcinoma. <i>Genes and Development</i> , 2016, 30, 1020-1033.	2.7	122
45	Tissue of origin dictates branched-chain amino acid metabolism in mutant <i>Kras</i> -driven cancers. <i>Science</i> , 2016, 353, 1161-1165.	6.0	447
46	Mutational landscape of <i>EGFR</i> , <i>MYC</i> , and <i>Kras</i> driven genetically engineered mouse models of lung adenocarcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E6409-E6417.	3.3	158
47	Circadian Rhythm Disruption Promotes Lung Tumorigenesis. <i>Cell Metabolism</i> , 2016, 24, 324-331.	7.2	366
48	Clonal dynamics following p53 loss of heterozygosity in Kras-driven cancers. <i>Nature Communications</i> , 2016, 7, 12685.	5.8	58
49	A Modular Assembly Platform for Rapid Generation of DNA Constructs. <i>Scientific Reports</i> , 2016, 6, 16836.	1.6	54
50	<i>PKM2</i> , cancer metabolism, and the road ahead. <i>EMBO Reports</i> , 2016, 17, 1721-1730.	2.0	384
51	Stromal Expression of miR-143/145 Promotes Neoangiogenesis in Lung Cancer Development. <i>Cancer Discovery</i> , 2016, 6, 188-201.	7.7	122
52	Environment Impacts the Metabolic Dependencies of Ras-Driven Non-Small Cell Lung Cancer. <i>Cell Metabolism</i> , 2016, 23, 517-528.	7.2	616
53	Applications of the CRISPR-Cas9 system in cancer biology. <i>Nature Reviews Cancer</i> , 2015, 15, 387-393.	12.8	340
54	Recombinase-based conditional and reversible gene regulation via XTR alleles. <i>Nature Communications</i> , 2015, 6, 8783.	5.8	31

#	ARTICLE	IF	CITATIONS
55	A versatile reporter system for CRISPR-mediated chromosomal rearrangements. <i>Genome Biology</i> , 2015, 16, 111.	13.9	52
56	The Comparative Pathology of Genetically Engineered Mouse Models for Neuroendocrine Carcinomas of the Lung. <i>Journal of Thoracic Oncology</i> , 2015, 10, 553-564.	0.5	100
57	Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma. <i>Nature Medicine</i> , 2015, 21, 1163-1171.	15.2	349
58	Regulatory T Cells in Tumor-Associated Tertiary Lymphoid Structures Suppress Anti-tumor T Cell Responses. <i>Immunity</i> , 2015, 43, 579-590.	6.6	360
59	Foxa2 and Cdx2 cooperate with Nkx2-1 to inhibit lung adenocarcinoma metastasis. <i>Genes and Development</i> , 2015, 29, 1850-1862.	2.7	87
60	Genetic Mouse Models of Cancer. , 2015, , 145-154.e2.		5
61	Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. <i>Nature Biotechnology</i> , 2014, 32, 551-553.	9.4	823
62	Genetic and Clonal Dissection of Murine Small Cell Lung Carcinoma Progression by Genome Sequencing. <i>Cell</i> , 2014, 156, 1298-1311.	13.5	241
63	Rapid modelling of cooperating genetic events in cancer through somatic genome editing. <i>Nature</i> , 2014, 516, 428-431.	13.7	353
64	Small RNA combination therapy for lung cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, E3553-61.	3.3	210
65	CRISPR-mediated direct mutation of cancer genes in the mouse liver. <i>Nature</i> , 2014, 514, 380-384.	13.7	673
66	Autophagy Is Required for Glucose Homeostasis and Lung Tumor Maintenance. <i>Cancer Discovery</i> , 2014, 4, 914-927.	7.7	450
67	LincRNA-p21 Activates p21 In cis to Promote Polycomb Target Gene Expression and to Enforce the G1/S Checkpoint. <i>Molecular Cell</i> , 2014, 54, 777-790.	4.5	412
68	KRAS and YAP1 Converge to Regulate EMT and Tumor Survival. <i>Cell</i> , 2014, 158, 171-184.	13.5	608
69	A Reversible Gene-Targeting Strategy Identifies Synthetic Lethal Interactions between MK2 and p53 in the DNA Damage Response In Vivo. <i>Cell Reports</i> , 2013, 5, 868-877.	2.9	85
70	PKM2 Isoform-Specific Deletion Reveals a Differential Requirement for Pyruvate Kinase in Tumor Cells. <i>Cell</i> , 2013, 155, 397-409.	13.5	429
71	Nkx2-1 Represses a Latent Gastric Differentiation Program in Lung Adenocarcinoma. <i>Molecular Cell</i> , 2013, 50, 185-199.	4.5	215
72	Genetically engineered mouse models of cancer reveal new insights about the antitumor immune response. <i>Current Opinion in Immunology</i> , 2013, 25, 192-199.	2.4	76

#	ARTICLE	IF	CITATIONS
73	Integrated cisomic and expression analysis of amplified <i>NKX2-1</i> in lung adenocarcinoma identifies <i>LMO3</i> as a functional transcriptional target. <i>Genes and Development</i> , 2013, 27, 197-210.	2.7	61
74	Differential <i>Tks5</i> isoform expression contributes to metastatic invasion of lung adenocarcinoma. <i>Genes and Development</i> , 2013, 27, 1557-1567.	2.7	62
75	Dominant Role of Oncogene Dosage and Absence of Tumor Suppressor Activity in <i>Nras</i> -Driven Hematopoietic Transformation. <i>Cancer Discovery</i> , 2013, 3, 993-1001.	7.7	60
76	Autophagy suppresses progression of K-ras-induced lung tumors to oncocytomas and maintains lipid homeostasis. <i>Genes and Development</i> , 2013, 27, 1447-1461.	2.7	529
77	<i>Pten</i> -Null Tumors Cohabiting the Same Lung Display Differential AKT Activation and Sensitivity to Dietary Restriction. <i>Cancer Discovery</i> , 2013, 3, 908-921.	7.7	36
78	Characterizing deformability and surface friction of cancer cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 7580-7585.	3.3	297
79	SnapShot: Lung Cancer Models. <i>Cell</i> , 2012, 149, 246-246.e1.	13.5	36
80	Expression of tumour-specific antigens underlies cancer immunoediting. <i>Nature</i> , 2012, 482, 405-409.	13.7	478
81	Proliferation and Tumorigenesis of a Murine Sarcoma Cell Line in the Absence of DICER1. <i>Cancer Cell</i> , 2012, 21, 848-855.	7.7	58
82	Nuclear factor I/B is an oncogene in small cell lung cancer. <i>Genes and Development</i> , 2011, 25, 1470-1475.	2.7	142
83	Caspase-2-Mediated Cleavage of Mdm2 Creates a p53-Induced Positive Feedback Loop. <i>Molecular Cell</i> , 2011, 43, 57-71.	4.5	139
84	Selective killing of K-ras mutant cancer cells by small molecule inducers of oxidative stress. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 8773-8778.	3.3	213
85	Hematopoiesis and leukemogenesis in mice expressing oncogenic <i>Nras</i> G12D from the endogenous locus. <i>Blood</i> , 2011, 117, 2022-2032.	0.6	132
86	Coordinate loss of a microRNA and protein-coding gene cooperate in the pathogenesis of 5q ⁺ syndrome. <i>Blood</i> , 2011, 118, 4666-4673.	0.6	97
87	Suppression of lung adenocarcinoma progression by <i>Nkx2-1</i> . <i>Nature</i> , 2011, 473, 101-104.	13.7	383
88	Endogenous T Cell Responses to Antigens Expressed in Lung Adenocarcinomas Delay Malignant Tumor Progression. <i>Cancer Cell</i> , 2011, 19, 72-85.	7.7	209
89	Requirement of c-Jun NH ₂ -Terminal Kinase for Ras-Initiated Tumor Formation. <i>Molecular and Cellular Biology</i> , 2011, 31, 1565-1576.	1.1	93
90	Response and Resistance to NF- κ B Inhibitors in Mouse Models of Lung Adenocarcinoma. <i>Cancer Discovery</i> , 2011, 1, 236-247.	7.7	116

#	ARTICLE	IF	CITATIONS
91	Uncoupling Cancer Mutations Reveals Critical Timing of p53 Loss in Sarcomagenesis. <i>Cancer Research</i> , 2011, 71, 4040-4047.	0.4	76
92	Progressive Genomic Instability in the FVB/KrasLA2 Mouse Model of Lung Cancer. <i>Molecular Cancer Research</i> , 2011, 9, 1339-1345.	1.5	21
93	Imaging Primary Lung Cancers in Mice to Study Radiation Biology. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 76, 973-977.	0.4	57
94	Stage-specific sensitivity to p53 restoration during lung cancer progression. <i>Nature</i> , 2010, 468, 572-575.	13.7	255
95	Chimeric mouse tumor models reveal differences in pathway activation between ERBB family and KRAS-dependent lung adenocarcinomas. <i>Nature Biotechnology</i> , 2010, 28, 71-78.	9.4	71
96	Tissue-specific p19 ^{Arf} regulation dictates the response to oncogenic K-ras. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 10184-10189.	3.3	54
97	Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer. <i>Genes and Development</i> , 2010, 24, 837-852.	2.7	174
98	HIF-2 α deletion promotes Kras-driven lung tumor development. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 14182-14187.	3.3	117
99	Suppression of Rev3, the catalytic subunit of Pol η , sensitizes drug-resistant lung tumors to chemotherapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 20786-20791.	3.3	160
100	NF- κ B Fans the Flames of Lung Carcinogenesis. <i>Cancer Prevention Research</i> , 2010, 3, 403-405.	0.7	27
101	A Large Intergenic Noncoding RNA Induced by p53 Mediates Global Gene Repression in the p53 Response. <i>Cell</i> , 2010, 142, 409-419.	13.5	1,919
102	p63 and p73 Transcriptionally Regulate Genes Involved in DNA Repair. <i>PLoS Genetics</i> , 2009, 5, e1000680.	1.5	120
103	Context-Dependent Transformation of Adult Pancreatic Cells by Oncogenic K-Ras. <i>Cancer Cell</i> , 2009, 16, 379-389.	7.7	305
104	Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. <i>Nature</i> , 2009, 458, 223-227.	13.7	3,801
105	Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. <i>Nature</i> , 2009, 462, 108-112.	13.7	2,707
106	Requirement for NF- κ B signalling in a mouse model of lung adenocarcinoma. <i>Nature</i> , 2009, 462, 104-107.	13.7	483
107	Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. <i>Nature Protocols</i> , 2009, 4, 1064-1072.	5.5	711
108	Dicer1 functions as a haploinsufficient tumor suppressor. <i>Genes and Development</i> , 2009, 23, 2700-2704.	2.7	391

#	ARTICLE	IF	CITATIONS
109	MicroRNAs and Cancer: Short RNAs Go a Long Way. <i>Cell</i> , 2009, 136, 586-591.	13.5	824
110	Synthetic Lethal Interaction between Oncogenic KRAS Dependency and STK33 Suppression in Human Cancer Cells. <i>Cell</i> , 2009, 137, 821-834.	13.5	510
111	Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. <i>Nature Genetics</i> , 2008, 40, 600-608.	9.4	514
112	Genetic Mouse Models of Cancer. , 2008, , 129-138.		0
113	A mouse plasma PeptideAtlas as a resource for disease proteomics. <i>Genome Biology</i> , 2008, 9, R93.	13.9	22
114	Targeted Deletion Reveals Essential and Overlapping Functions of the miR-17~1/492 Family of miRNA Clusters. <i>Cell</i> , 2008, 132, 875-886.	13.5	1,504
115	Growth-Inhibitory and Tumor- Suppressive Functions of p53 Depend on Its Repression of CD44 Expression. <i>Cell</i> , 2008, 134, 62-73.	13.5	381
116	Suppression of non-small cell lung tumor development by the <i>let-7</i> microRNA family. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 3903-3908.	3.3	808
117	Regulated Expression of a Tumor-Associated Antigen Reveals Multiple Levels of T-Cell Tolerance in a Mouse Model of Lung Cancer. <i>Cancer Research</i> , 2008, 68, 9459-9468.	0.4	45
118	Sprouty-2 regulates oncogenic K-ras in lung development and tumorigenesis. <i>Genes and Development</i> , 2007, 21, 694-707.	2.7	120
119	Modulation of tumor induction and progression of oncogenic K-ras-positive tumors in the presence of TGF- 1 haploinsufficiency. <i>Carcinogenesis</i> , 2007, 28, 2589-2596.	1.3	11
120	Dominant-Negative but not Gain-of-Function Effects of a p53.R270H Mutation in Mouse Epithelium Tissue after DNA Damage. <i>Cancer Research</i> , 2007, 67, 4648-4656.	0.4	40
121	Requirement for Rac1 in a K-rasâ€œInduced Lung Cancer in the Mouse. <i>Cancer Research</i> , 2007, 67, 8089-8094.	0.4	148
122	Roles of microRNAs in cancer and development. , 2007, , 322-337.		0
123	Impaired microRNA processing enhances cellular transformation and tumorigenesis. <i>Nature Genetics</i> , 2007, 39, 673-677.	9.4	1,351
124	A spatially and temporally restricted mouse model of soft tissue sarcoma. <i>Nature Medicine</i> , 2007, 13, 992-997.	15.2	274
125	Murine bilateral retinoblastoma exhibiting rapid-onset, metastatic progression and N-myc gene amplification. <i>EMBO Journal</i> , 2007, 26, 784-794.	3.5	69
126	Restoration of p53 function leads to tumour regression in vivo. <i>Nature</i> , 2007, 445, 661-665.	13.7	1,662

#	ARTICLE	IF	CITATIONS
127	A functional switch from lung cancer resistance to susceptibility at the Pas1 locus in Kras2LA2 mice. <i>Nature Genetics</i> , 2006, 38, 926-930.	9.4	67
128	Comparison of gene expression and DNA copy number changes in a murine model of lung cancer. <i>Genes Chromosomes and Cancer</i> , 2006, 45, 338-348.	1.5	42
129	Mist1-KrasG12D Knock-In Mice Develop Mixed Differentiation Metastatic Exocrine Pancreatic Carcinoma and Hepatocellular Carcinoma. <i>Cancer Research</i> , 2006, 66, 242-247.	0.4	132
130	Cyclooxygenase-1 Is Overexpressed in Multiple Genetically Engineered Mouse Models of Epithelial Ovarian Cancer. <i>Cancer Research</i> , 2006, 66, 2527-2531.	0.4	70
131	The Related Retinoblastoma (pRb) and p130 Proteins Cooperate to Regulate Homeostasis in the Intestinal Epithelium. <i>Journal of Biological Chemistry</i> , 2006, 281, 638-647.	1.6	66
132	ROS Fusion Tyrosine Kinase Activates a SH2 Domain-Containing Phosphatase-2/Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Signaling Axis to Form Glioblastoma in Mice. <i>Cancer Research</i> , 2006, 66, 7473-7481.	0.4	145
133	An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis. <i>Nature Genetics</i> , 2005, 37, 48-55.	9.4	392
134	Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. <i>Nature Medicine</i> , 2005, 11, 63-70.	15.2	785
135	MicroRNA expression profiles classify human cancers. <i>Nature</i> , 2005, 435, 834-838.	13.7	8,931
136	Tumor predisposition in mice mutant for p63 and p73: Evidence for broader tumor suppressor functions for the p53 family. <i>Cancer Cell</i> , 2005, 7, 363-373.	7.7	455
137	Mammalian RNAi: a practical guide. <i>BioTechniques</i> , 2005, 39, 215-224.	0.8	121
138	The Differential Effects of Mutant p53 Alleles on Advanced Murine Lung Cancer. <i>Cancer Research</i> , 2005, 65, 10280-10288.	0.4	488
139	Lack of p53 Ser389 Phosphorylation Predisposes Mice to Develop 2-Acetylaminofluorene-Induced Bladder Tumors but not Ionizing Radiation-Induced Lymphomas. <i>Cancer Research</i> , 2005, 65, 3610-3616.	0.4	35
140	Future of Early Detection of Lung Cancer: The Role of Mouse Models. <i>Clinical Cancer Research</i> , 2005, 11, 4999s-5003s.	3.2	20
141	Mice Expressing a Mammary Gland-Specific R270H Mutation in the p53 Tumor Suppressor Gene Mimic Human Breast Cancer Development. <i>Cancer Research</i> , 2005, 65, 8166-8173.	0.4	59
142	Use of gene expression profiling to direct in vivo molecular imaging of lung cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 14404-14409.	3.3	133
143	Identification of Bronchioalveolar Stem Cells in Normal Lung and Lung Cancer. <i>Cell</i> , 2005, 121, 823-835.	13.5	2,023
144	p53 Family Members: p63 and p73. , 2005, , 187-198.		1

#	ARTICLE	IF	CITATIONS
145	Increased Sensitivity to UV Radiation in Mice with a p53 Point Mutation at Ser389. <i>Molecular and Cellular Biology</i> , 2004, 24, 8884-8894.	1.1	116
146	Susceptibility to astrocytoma in mice mutant for Nf1 and Trp53 is linked to chromosome 11 and subject to epigenetic effects. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 13008-13013.	3.3	89
147	Cre-lox-regulated conditional RNA interference from transgenes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 10380-10385.	3.3	575
148	Cell type-specific effects of Rb deletion in the murine retina. <i>Genes and Development</i> , 2004, 18, 1681-1694.	2.7	208
149	RB signaling prevents replication-dependent DNA double-strand breaks following genotoxic insult. <i>Nucleic Acids Research</i> , 2004, 32, 25-34.	6.5	87
150	Defective apoptosis and B-cell lymphomas in mice with p53 point mutation at Ser 23. <i>EMBO Journal</i> , 2004, 23, 3689-3699.	3.5	116
151	The Rb tumor suppressor is required for stress erythropoiesis. <i>EMBO Journal</i> , 2004, 23, 4319-4329.	3.5	91
152	Activation of the p53-dependent G1 checkpoint response in mouse embryo fibroblasts depends on the specific DNA damage inducer. <i>Oncogene</i> , 2004, 23, 973-980.	2.6	97
153	Discrete signaling pathways participate in RB-dependent responses to chemotherapeutic agents. <i>Oncogene</i> , 2004, 23, 4107-4120.	2.6	41
154	Mutation at p53 serine 389 does not rescue the embryonic lethality in mdm2 or mdm4 null mice. <i>Oncogene</i> , 2004, 23, 7644-7650.	2.6	18
155	Endogenous oncogenic K-rasG12D stimulates proliferation and widespread neoplastic and developmental defects. <i>Cancer Cell</i> , 2004, 5, 375-387.	7.7	710
156	Classification of Proliferative Pulmonary Lesions of the Mouse. <i>Cancer Research</i> , 2004, 64, 2307-2316.	0.4	313
157	Mutant p53 Gain of Function in Two Mouse Models of Li-Fraumeni Syndrome. <i>Cell</i> , 2004, 119, 847-860.	13.5	1,140
158	Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease. <i>Journal of Clinical Investigation</i> , 2004, 113, 528-538.	3.9	231
159	A big step in the study of small cell lung cancer. <i>Cancer Cell</i> , 2003, 4, 163-166.	7.7	50
160	Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. <i>Cancer Cell</i> , 2003, 4, 437-450.	7.7	2,150
161	Perp Is a Mediator of p53-Dependent Apoptosis in Diverse Cell Types. <i>Current Biology</i> , 2003, 13, 1985-1990.	1.8	97
162	Acute mutation of retinoblastoma gene function is sufficient for cell cycle re-entry. <i>Nature</i> , 2003, 424, 223-228.	13.7	501

#	ARTICLE	IF	CITATIONS
163	Merlin, the Product of the Nf2 Tumor Suppressor Gene, Is an Inhibitor of the p21-Activated Kinase, Pak1. <i>Molecular Cell</i> , 2003, 12, 841-849.	4.5	222
164	Recapitulation of the Effects of the Human Papillomavirus Type 16 E7 Oncogene on Mouse Epithelium by Somatic Rb Deletion and Detection of pRb-Independent Effects of E7 In Vivo. <i>Molecular and Cellular Biology</i> , 2003, 23, 9094-9103.	1.1	103
165	Targeted Deletion Reveals an Essential Function for the Telomere Length Regulator Trf1. <i>Molecular and Cellular Biology</i> , 2003, 23, 6533-6541.	1.1	150
166	Dynamic regulation of the Ras pathway via proteolysis of the NF1 tumor suppressor. <i>Genes and Development</i> , 2003, 17, 449-454.	2.7	120
167	Neurofibromatosis Type 1. , 2003, 222, 223-237.		5
168	Marked Regression of Metastatic Pilocytic Astrocytoma During Treatment With Imatinib Mesylate (STI-571, Gleevec): A Case Report and Laboratory Investigation. <i>Journal of Pediatric Hematology/Oncology</i> , 2003, 25, 644-648.	0.3	21
169	Rb and N- ras Function Together To Control Differentiation in the Mouse. <i>Molecular and Cellular Biology</i> , 2003, 23, 5256-5268.	1.1	49
170	Merlin Phosphorylation by p21-activated Kinase 2 and Effects of Phosphorylation on Merlin Localization. <i>Journal of Biological Chemistry</i> , 2002, 277, 10394-10399.	1.6	213
171	Tumor Suppression by a Severely Truncated Species of Retinoblastoma Protein. <i>Molecular and Cellular Biology</i> , 2002, 22, 3103-3110.	1.1	25
172	ARF mutation accelerates pituitary tumor development in Rb+/- mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 16865-16870.	3.3	42
173	Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 2948-2953.	3.3	176
174	Cancer Modeling in the Modern Era. <i>Cell</i> , 2002, 108, 135-144.	13.5	348
175	An Induced Ets Repressor Complex Regulates Growth Arrest during Terminal Macrophage Differentiation. <i>Cell</i> , 2002, 109, 169-180.	13.5	90
176	Taking the Study of Cancer Cell Survival to a New Dimension. <i>Cell</i> , 2002, 111, 923-925.	13.5	279
177	Technologically advanced cancer modeling in mice. <i>Current Opinion in Genetics and Development</i> , 2002, 12, 105-110.	1.5	77
178	Defective proliferative responses in B lymphocytes and thymocytes that lack neurofibromin. <i>Molecular Immunology</i> , 2002, 38, 701-708.	1.0	25
179	Thinking beyond the tumor cell: Nf1 haploinsufficiency in the tumor environment. <i>Cancer Cell</i> , 2002, 1, 408-410.	7.7	30
180	ARF Is Not Required for Apoptosis in Rb Mutant Mouse Embryos. <i>Current Biology</i> , 2002, 12, 159-163.	1.8	70

#	ARTICLE	IF	CITATIONS
181	Cellular transformation by a FERM domain mutant of the Nf2 tumor suppressor gene. <i>Oncogene</i> , 2002, 21, 5990-5997.	2.6	42
182	Mechanism for the learning deficits in a mouse model of neurofibromatosis type 1. <i>Nature</i> , 2002, 415, 526-530.	13.7	541
183	p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. <i>Nature</i> , 2002, 416, 560-564.	13.7	775
184	The Nf2 Tumor Suppressor, Merlin, Functions in Rac-Dependent Signaling. <i>Developmental Cell</i> , 2001, 1, 63-72.	3.1	311
185	NF1 Tumor Suppressor Gene Function. <i>Cell</i> , 2001, 104, 593-604.	13.5	553
186	Genetically engineered mouse models of astrocytoma: GEMs in the rough?. <i>Seminars in Cancer Biology</i> , 2001, 11, 177-190.	4.3	28
187	STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. <i>Oncogene</i> , 2001, 20, 5054-5058.	2.6	643
188	Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. <i>Nature</i> , 2001, 410, 1111-1116.	13.7	1,060
189	Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. <i>Genes and Development</i> , 2001, 15, 3243-3248.	2.7	1,663
190	Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects. <i>Nature Genetics</i> , 2000, 26, 109-113.	9.4	379
191	Role for the p53 homologue p73 in E2F-1-induced apoptosis. <i>Nature</i> , 2000, 407, 645-648.	13.7	656
192	Targeted disruption of the three Rb-related genes leads to loss of G1 control and immortalization. <i>Genes and Development</i> , 2000, 14, 3037-3050.	2.7	546
193	Nf1 and Gmcsf Interact in Myeloid Leukemogenesis. <i>Molecular Cell</i> , 2000, 5, 189-195.	4.5	132
194	PERP, an apoptosis-associated target of p53, is a novel member of the PMP-22/gas3 family. <i>Genes and Development</i> , 2000, 14, 704-718.	2.7	310
195	In Vitro and In Vivo Effects of a Farnesyltransferase Inhibitor on Nf1-Deficient Hematopoietic Cells. <i>Blood</i> , 1999, 94, 2469-2476.	0.6	81
196	Myeloid Malignancies Induced by Alkylating Agents in Nf1 Mice. <i>Blood</i> , 1999, 93, 3617-3623.	0.6	55
197	Modeling human lung cancer in mice: similarities and shortcomings. <i>Oncogene</i> , 1999, 18, 5318-5324.	2.6	121
198	The retinoblastoma gene family in differentiation and development. <i>Oncogene</i> , 1999, 18, 7873-7882.	2.6	362

#	ARTICLE	IF	CITATIONS
199	Insights into cancer from transgenic mouse models. , 1999, 187, 43-60.		113
200	Mouse Models of Tumor Development in Neurofibromatosis Type 1 . Science, 1999, 286, 2172-2176.	6.0	441
201	Myeloid Malignancies Induced by Alkylating Agents in Nf1 Mice. Blood, 1999, 93, 3617-3623.	0.6	6
202	Loss of E2F-1 reduces tumorigenesis and extends the lifespan of Rb1(+/ \hat{a}) mice. Nature Genetics, 1998, 18, 360-364.	9.4	274
203	Tumor suppressor mutations in mice: the next generation. Current Opinion in Genetics and Development, 1998, 8, 304-310.	1.5	15
204	Mutation of E2f-1 Suppresses Apoptosis and Inappropriate S Phase Entry and Extends Survival of Rb-Deficient Mouse Embryos. Molecular Cell, 1998, 2, 293-304.	4.5	361
205	p21 Is a Critical CDK2 Regulator Essential for Proliferation Control in Rb-deficient Cells. Journal of Cell Biology, 1998, 141, 503-514.	2.3	145
206	Regulation of the Neurofibromatosis Type 2 Tumor Suppressor Protein, Merlin, by Adhesion and Growth Arrest Stimuli. Journal of Biological Chemistry, 1998, 273, 7757-7764.	1.6	113
207	Nf1 Regulates Hematopoietic Progenitor Cell Growth and Ras Signaling in Response to Multiple Cytokines. Journal of Experimental Medicine, 1998, 187, 1893-1902.	4.2	140
208	RhoA-Dependent Phosphorylation and Relocalization of ERM Proteins into Apical Membrane/Actin Protrusions in Fibroblasts. Molecular Biology of the Cell, 1998, 9, 403-419.	0.9	171
209	p130 Is Dispensable in Peripheral T Lymphocytes: Evidence for Functional Compensation by p107 and pRB. Molecular and Cellular Biology, 1998, 18, 206-220.	1.1	81
210	Involvement of p53 and p21 in Cellular Defects and Tumorigenesis in Atm \hat{a} / \hat{a} Mice. Molecular and Cellular Biology, 1998, 18, 4385-4390.	1.1	94
211	Characterization of the p53-Dependent Postmitotic Checkpoint following Spindle Disruption. Molecular and Cellular Biology, 1998, 18, 1055-1064.	1.1	466
212	A mouse model for the learning and memory deficits associated with neurofibromatosis type I. Nature Genetics, 1997, 15, 281-284.	9.4	336
213	Deletion of p21 cannot substitute for p53 loss in rescue of mdm2 null lethality. Nature Genetics, 1997, 16, 336-337.	9.4	16
214	Double indemnity: p53, BRCA and cancer. Nature Medicine, 1997, 3, 721-722.	15.2	105
215	TUMOR SUPPRESSOR GENE MUTATIONS IN MICE. Annual Review of Genetics, 1996, 30, 603-636.	3.2	104
216	Tumor Induction and Tissue Atrophy in Mice Lacking E2F-1. Cell, 1996, 85, 537-548.	13.5	671

#	ARTICLE	IF	CITATIONS
217	Mechanisms of carcinogenesis and the mutant mouse. <i>Current Opinion in Genetics and Development</i> , 1996, 6, 65-70.	1.5	26
218	Lessons from the p53 mutant mouse. <i>Journal of Cancer Research and Clinical Oncology</i> , 1996, 122, 319-327.	1.2	33
219	Nf1 gene targeting: toward models and mechanisms. <i>Seminars in Cancer Biology</i> , 1996, 7, 291-298.	4.3	10
220	Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells. <i>Nature Genetics</i> , 1996, 12, 144-148.	9.4	555
221	Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. <i>Nature</i> , 1996, 379, 88-91.	13.7	2,223
222	Cell-cycle control and its watchman. <i>Nature</i> , 1996, 381, 643-644.	13.7	278
223	A subset of p53-deficient embryos exhibit exencephaly. <i>Nature Genetics</i> , 1995, 10, 175-180.	9.4	544
224	Radiation-induced cell cycle arrest compromised by p21 deficiency. <i>Nature</i> , 1995, 377, 552-557.	13.7	1,218
225	Vascular system defects and neuronal apoptosis in mice lacking Ras GTPase-activating protein. <i>Nature</i> , 1995, 377, 695-701.	13.7	357
226	Characterization of pheochromocytomas in a mouse strain with a targeted disruptive mutation of the neurofibromatosis gene Nf1. <i>Endocrine Pathology</i> , 1995, 6, 323-335.	5.2	40
227	Tumour predisposition in mice heterozygous for a targeted mutation in Nf1. <i>Nature Genetics</i> , 1994, 7, 353-361.	9.4	731
228	Cooperative tumorigenic effects of germline mutations in Rb and p53. <i>Nature Genetics</i> , 1994, 7, 480-484.	9.4	379
229	p53-dependent apoptosis produced by Rb-deficiency in the developing mouse lens. <i>Nature</i> , 1994, 371, 72-74.	13.7	625
230	Sunburn and p53 in the onset of skin cancer. <i>Nature</i> , 1994, 372, 773-776.	13.7	1,724
231	Tumor spectrum analysis in p53-mutant mice. <i>Current Biology</i> , 1994, 4, 1-7.	1.8	1,903
232	p53-Dependent apoptosis suppresses tumor growth and progression in vivo. <i>Cell</i> , 1994, 78, 703-711.	13.5	873
233	p53 is required for radiation-induced apoptosis in mouse thymocytes. <i>Nature</i> , 1993, 362, 847-849.	13.7	2,829
234	Generation of normal lymphocyte populations by Rb-deficient embryonic stem cells. <i>Current Biology</i> , 1993, 3, 405-413.	1.8	37

#	ARTICLE	IF	CITATIONS
235	p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. <i>Cell</i> , 1993, 74, 957-967.	13.5	2,848
236	Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. <i>Cell</i> , 1992, 70, 923-935.	13.5	1,345
237	A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. <i>Cell</i> , 1992, 71, 587-597.	13.5	3,006
238	Effects of an Rb mutation in the mouse. <i>Nature</i> , 1992, 359, 295-300.	13.7	1,730
239	Characterization of ribosomal frameshifting in HIV-1 gag-pol expression. <i>Nature</i> , 1988, 331, 280-283.	13.7	928
240	Signals for ribosomal frameshifting in the rous sarcoma virus gag-pol region. <i>Cell</i> , 1988, 55, 447-458.	13.5	647